Skip to content
sellWeak cluster of 3

Gwenn Hansen sold $81k of NRIX

Chief Scientific Officer at Nurix Therapeutics, Inc.. 4,895 shares at an average of $16.60, traded Jan 30, 2026, filed Jan 30, 2026.

Warning score
24
Value
$81k
4,895 shares
Holdings after
83,672
-6% from before
From 52-week low
+100%
low $8.24, close $16.52
From 52-week high
-23%
high $21.47, as of Jan 30, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $81k at market
    +9
  • Share of holdings sold
    Sold 5.5% of holdings
    0
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -3.3%, 3m +1.8%, 6m +40.5%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

NRIXOct 12, 2026 · close 22.16
Since filing Jan 30, 2026: +34.1%SPY +13.3% · excess +20.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001817160-26-000002, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 30, 2026MOption exercise
Common Stock
+3,207$0.00$079,958Jan 30, 2026
Jan 30, 2026MOption exercise
Common Stock
+2,000$0.00$081,958Jan 30, 2026
Jan 30, 2026MOption exercise
Common Stock
+3,750$0.00$085,708Jan 30, 2026
Jan 30, 2026MOption exercise
Common Stock
+2,859$0.00$088,567Jan 30, 2026
Jan 30, 2026SOpen-market sale
Common Stock
-4,797$16.58$80k83,770Jan 30, 2026
Jan 30, 2026SOpen-market sale
Common Stock
-98$17.37$1,70283,672Jan 30, 2026
Jan 30, 2026MOption exercise
Restricted Stock Unitsderivative
-3,207$0.00$00Jan 30, 2026
Jan 30, 2026MOption exercise
Restricted Stock Unitsderivative
-2,000$0.00$02,000Jan 30, 2026
Jan 30, 2026MOption exercise
Restricted Stock Unitsderivative
-3,750$0.00$018,750Jan 30, 2026
Jan 30, 2026MOption exercise
Restricted Stock Unitsderivative
-2,859$0.00$025,725Jan 30, 2026

Related signals

Other insiders at Nurix Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
1Weak
NRIXsell10b5-1
Nurix Therapeutics, Inc.
Christine Ring
Chief Legal Officer
$134k
5,786 shares
-39%
9Weak
NRIXsell 210b5-1
Nurix Therapeutics, Inc.
Christine Ring
Chief Legal Officer
$149k
5,787 shares
-39%
0Weak
NRIXsell 210b5-1
Nurix Therapeutics, Inc.
Gwenn Hansen
Chief Scientific Officer
$37k
1,452 shares
-1%
20Weak
NRIXsell 310b5-1
Nurix Therapeutics, Inc.
Gwenn Hansen
Chief Scientific Officer
$100k
4,111 shares
-3%
5Weak
NRIXsell 310b5-1
Nurix Therapeutics, Inc.
Gwenn Hansen
Chief Scientific Officer
$109k
4,356 shares
-4%
32Weak
NRIXsell 310b5-1
Nurix Therapeutics, Inc.
Hans van Houte
Chief Financial Officer
$116k
4,761 shares
-11%
31Weak
NRIXsell 310b5-1
Nurix Therapeutics, Inc.
Christine Ring
Chief Legal Officer
$382k
16,589 shares
-65%
24Weak
NRIXsell 3
Nurix Therapeutics, Inc.
Gwenn Hansen
Chief Scientific Officer
$90k
3,847 shares
-3%
29Weak
NRIXsell 3
Nurix Therapeutics, Inc.
Christine Ring
Chief Legal Officer
$90k
3,847 shares
-16%
30Weak
NRIXsell 3
Nurix Therapeutics, Inc.
Hans van Houte
Chief Financial Officer
$67k
2,845 shares
-6%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Gwenn Hansen sold $81k of NRIX | InsiderTell